Latest news

25 October 2026

Johnson & Johnson reports 75% RECIST response for JNJ-6143 in advanced prostate cancer

Phase 1 data show 75% imaging response and deep PSA declines at 50 mg; most adverse events were mild–moderate and 50 mg will advance to Phase 2.
24 October 2026

Lilly's Sofetabart Mipitecan shows 79% cORR in platinum‑sensitive ovarian cancer

Sofe‑M plus bevacizumab produced a 79% confirmed objective response rate and 100% disease control in platinum‑sensitive ovarian cancer, with activity across FRα levels and prior PARPi exposure.
24 October 2026

Bayer: Darolutamide with ADT and RT Cuts Metastasis-or-Death Risk 58% in High‑Risk Prostate Cancer

Interim Phase III DASL-HiCaP results show darolutamide added to ADT and radiation significantly improves metastasis-free survival versus placebo in high‑risk patients.
24 October 2026

Johnson & Johnson: Perioperative ERLEADA plus ADT cuts recurrence or death by 62% vs surgery alone in high-risk prostate cancer

Apalutamide plus short-course ADT given six months around prostatectomy improved event-free and metastasis-free survival and delayed need for additional therapy in a 408‑patient randomized substudy.
24 October 2026

Amgen: IMDELLTRA plus IMFINZI cuts death risk 58% in first‑line maintenance ES‑SCLC

Phase 3 DeLLphi‑305: IMDELLTRA with durvalumab raised median OS to 21.1 vs 12.7 months, tripled PFS, and produced ~80% one‑year survival versus 53%.
24 October 2026

GSK: Jemperli achieves 76% complete response in MSI‑H/dMMR locally advanced rectal cancer

76% of evaluable patients had no detectable cancer after dostarlimab monotherapy; responders show no recurrences after more than two years; safety consistent with known profile.
24 October 2026

Genmab and Incyte to test petosemtamab with KRAS G12D inhibitor in first‑line mCRC

Phase 1/2 trial will combine an EGFR/LGR5 bispecific antibody with a KRAS G12D inhibitor plus chemotherapy as first‑line treatment for KRAS G12D‑mutant metastatic colorectal cancer.
23 October 2026

Genmab: Rinatabart Sesutecan (Rina‑S) significantly improves PFS and OS in platinum‑resistant ovarian cancer

Phase 3 RAINFOL‑02 shows statistically significant and clinically meaningful PFS and OS benefits versus investigator’s choice chemotherapy in platinum‑resistant ovarian cancer.
23 October 2026

Roche: sefaxersen cuts proteinuria 43.1% in phase III IgAN trial

Phase III data show once‑monthly ASO sefaxersen reduced proteinuria versus placebo at 37 weeks in adults with IgA nephropathy, with consistent subgroup effects and no new safety signals.
23 October 2026

AMA and EMA joint guidance to accelerate BDBV Ebola vaccine trials

Guidance to help start Bundibugyo virus vaccine trials rapidly while maintaining safety: allows some animal-study waivers for known platforms, recommends early African trials, single-dose preference, and ring trial design.
23 October 2026

Novo Nordisk's Awiqli approved by FDA as first once-weekly basal insulin for children 10+ with type 2 diabetes

Reduces basal injections from seven to one per week; insulin icodec‑abae is U‑700, indicated for ages ≥10, supported by pediatric PK and ONWARDS clinical data.
23 October 2026

European Commission opens antitrust probe into Omya over calcium carbonate supply

Formal EU investigation into alleged exclusivity obligations and rebates in calcium carbonate sales to the paper industry, assessing potential abuse of dominance.
23 October 2026

GSK Mo‑Rez shows 62% confirmed response and 12.2‑month median DoR in platinum‑resistant ovarian cancer

Phase Ib BEHOLD‑1 reports durable responses and 11.1‑month median PFS at the selected phase III dose; safety predominantly haematologic with most grade ≥3 events.
23 October 2026

Aluminerie Alouette secures $28.5 million from Strategic Response Fund

Funding backs modernization to cut emissions and improve energy efficiency; two SRF-backed projects ($135M) target carbon anodes and bath-covering particle size, due 2027.
23 October 2026

BHP CEO Brandon Craig outlines priorities at 2026 AGM

Craig makes safety his first priority after two recent site fatalities, flags FY2026 results (US$33bn EBITDA; US$13bn profit), confirms Jansen first production mid next year and 3–4% CAGR to 2035.
23 October 2026

Eni boosts shareholder returns and upgrades 2026 outlook

Proforma gearing at a historic low of 9% and adjusted CFFO lifted to €16.5bn; underlying E&P output +7% to 1.83 mln boe/d. Strategic deals include Junin 5 relaunch and asset monetisations.
23 October 2026

Takeda: Arcotatug Tavatecan (TAK‑921) improves OS and PFS in Phase 3 gastric cancer trial

Phase 3 G‑HOPE‑001 met dual endpoints in CLDN18.2‑positive advanced G/GEJA—median OS 10.2 vs 6.9 months and PFS 7.1 vs 3.1 months versus physician’s choice.
23 October 2026

Johnson & Johnson presents >25 solid tumor abstracts and new clinical data at ESMO 2026

New clinical results include first-in-human data for oral RIPTAC JNJ-6143 in mCRPC, late-breaking PROTEUS Phase 3 prostate results, and expanded RYBREVANT FASPRO datasets across lung and head & neck cancers.
23 October 2026

PETRONAS, TotalEnergies and Mitsui form JV to develop Southern CCS Hub storage offshore Malaysia

JV will develop offshore CO2 storage targeting up to 5 Mtpa injection; first injection targeted by 2031; supports Malaysia's Southern CCS Hub and potential cross-border CO2 shipments.
22 October 2026

QatarEnergy to buy 4 MTPA of U.S. LNG from Cheniere through 2054

Up to 4 MTPA of U.S. Gulf Coast LNG on an FOB basis from Sabine Pass and Corpus Christi, with deliveries expected to begin in 2031 and continue through 2054.
22 October 2026

Aibel wins FEED contract for Wisting production-vessel topsides

Front-end engineering and design study for the production-vessel topsides will involve about 250 people, includes an EPma option; concept selection by end‑2026 and FID planned late‑2027.
22 October 2026

BASF launches Voraxor and Zidua PLUS herbicides for 2027 season

Two herbicides: trifludimoxizan-based Voraxor for rapid burndown and Zidua PLUS for flexible pre-/post-emergence use with strong, >95% residual control at 60 days.
22 October 2026

Heidelberg Materials pauses GeZero CCS project in Geseke

Pause of a local CCS project due to immature CO₂ transport and storage value chains and insufficient economic conditions. Geseke plant operations continue; other CCS projects proceed.
22 October 2026

Merck and Moderna present Phase 3 INTerpath‑001: intismeran + KEYTRUDA reduces recurrence in resected stage IIB–IV melanoma

Intismeran plus pembrolizumab cut risk of recurrence or death 42% overall and 58% after six months; distant‑metastasis‑free survival also improved; safety profile consistent.
22 October 2026

Lilly breaks ground on $5 billion Richmond site for ADCs and integrated API/finished-medicine manufacturing

$5 billion Richmond facility will produce antibody-drug conjugates with integrated API and finished-medicine capacity, add 650 high-wage roles, and fund training with a $40 million commitment.
22 October 2026

Aemetis brings two more dairy biogas digesters online

Two digesters added to a 14-unit network feeding 36 miles of pipeline to a Keyes RNG plant; Keyes fueling station to begin truck deliveries in November 2026.
22 October 2026

DuPont launches AmberChrom™ SIL silica gel for peptide purification

Reverse-phase silica media for GLP‑1 and other peptides; available in C8 and C18 chemistries for high-resolution separations and integration with AmberChrom polymeric resins from development to manufacturing.
22 October 2026

LANXESS debuts Rely+On Medero disinfectant at Medica 2026

New broad-spectrum disinfectant active within minutes against bacteria, spores, fungi, viruses and biofilms; cleared as an EU Class IIa medical-device disinfectant and BPR Product Type 2.
22 October 2026

Groundbreaking for United Capital Fertilizer Complex in Lusaka

Zambian president and Chinese ambassador attended the groundbreaking ceremony on October 20.
22 October 2026

Dow Q3 2026 results

Sales rose to $11.3 billion and operating EBIT improved to $887 million; operating EPS returned to positive and free cash flow was $1.1 billion amid cost and asset actions.

Next →